Live Breaking News & Updates on கனடியன் காப்புரிமை
Stay updated with breaking news from கனடியன் காப்புரிமை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Federal Court upholds validity of one pneumococcal vaccine patent, but holds two other patents invalid | Smart & Biggar jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
International Water-Guard Industries Inc. (IWG) receives Patents for their Intelligent Pre-Select Water Quantity System Brand Story Canadian Patent No. 2,984,308 and USA Patent No. US 10,815,007 B2 IWG s Intelligent Water Quantity Pre-Select System gives airlines control over the amount of water uploaded into the aircraft by providing real-time data on how much water is used on every flight. By uploading more water than needed, airlines carry and burn more fuel. The typical size of a potable water tank on a commercial narrow-body jet is 60 gallons, which full, weighs approximately 500lbs. The actual water-usage data collected from IWG s Pre-Select System is proving to airlines they can save up to 400lbs per flight by only filling what they need. 400lbs saved every flight can mean millions of dollars in annual fuel savings for large airlines. Furthermore, this System from IWG saves more weight per flight than the combined usual airline weight-saving initiative ....
To embed, copy and paste the code into your website or blog: In the first appellate decision relating to Certificates of Supplementary Protection (CSPs), the Federal Court of Appeal has allowed the appeal of the Minister of Health (the Minister), setting aside the lower court judgment. In a unanimous decision released on April 14, 2021, the Federal Court of Appeal in Canada (Health) v Glaxosmithkline Biologicals S.A., 2021 FCA 71 found that the Federal Court (see article here) did not correctly apply the applicable standard of review. The Decision Under Review The Minister had found that SHRINGIX contained only one medicinal ingredient a Varicella Zoster Virus (VZV) gE antigen, and that the adjuvant in SHINGRIX was not a medicinal ingredient. ....
Merck argued Health Canada unreasonably held that the Time Limits Act) did not have the effect of suspending this 30-day time period. The Time Limits Act suspended a number of federally-legislated deadlines, including time limits related to limitation periods for commencing a court proceeding. Merck argued that subsection 4(6) functions as a “gateway” to the summary litigation provisions of the PMNOC Regulations and therefore the 30-day time period is a “limitation period within a limitation period”. The Federal Court disagreed, holding that the listing of a patent on the Patent Register is too remote from the commencement of a court proceeding: it is not inextricably connected to a prospective civil action, it does not cause time to begin running, there is no precipitating event, there is no defendant at the time of the listing and it is not even the most proximate step to a possible court proceeding. ....
Introduction The Federal Court of Appeal (FCA) recently dismissed Apotex s appeal of the Federal Court decision which held that the claims of Canadian Patent 2,527,646 (the 646 patent) were valid and prohibited the minister of health from issuing a notice of compliance to Apotex for its lisdexamfetamine (LDX) product (Shire s VYVANSE) until the expiry of the 646 patent ( The prohibition application under the pre-amended Patented Medicines (Notice of Compliance) Regulations was consolidated with Apotex s action seeking a declaration of invalidity and non-infringement. Apotex appealed both judgments. Amphetamine was an established treatment for conditions such as attention deficit hyperactivity disorder but as it is an immediate release compound, it requires patients to take doses frequently throughout the day. LDX is a prodrug of amphetamine that provides sustained release and reduces abuse potential. ....